Biotech companies continue to strike while the capital markets are hot, with an IPO from San Diego’s Celladon Corp. expected to debut this week.

A Cooley team led by partner Jason Kent is advising the clinical-stage cardiovascular company. Latham & Watkins, led by partner Cheston Larson, is working with underwriters J.P. Morgan and Barclays. A filing with the U.S. Securities and Exchange Commission disclosed that Cooley owns less than 1 percent of the company’s outstanding stock.